Also Known As: Desyrel, Oleptro, Beneficat, Deprax, Desirel, Molipaxin, Thombran, Trialodine, Trittico, Mesyrel, Trazodone
Trazodone (also sold under the brand names Desyrel, Oleptro, Beneficat, Deprax, Desirel, Molipaxin, Thombran, Trazorel, Trialodine, Trittico, and Mesyrel) is an antidepressant of the serotonin antagonist and reuptake inhibitor (SARI) class. It is a phenylpiperazine compound. Trazodone also has anxiolytic and hypnotic effects. Trazodone has considerably less prominent anticholinergic (dry mouth, constipation, tachycardia) and sexual side effects than most of the tricyclic antidepressants (TCAs).
Trazodone was originally discovered and developed in Italy in the 1960s by Angelini Research Laboratories as a second-generation antidepressant. It was developed according to the mental pain hypothesis, which was postulated from studying patients and which proposes that major depression is associated with a decreased pain threshold. Trazodone was patented and marketed in many countries all over the world. It was approved by the Food and Drug Administration (FDA) at the end of 1981.
- Unipolar depression, with or without anxiety
- Bipolar depression, in some circumstances
- Insomnia (in some countries, this is an off-label use)
- Control of nightmares or other sleep disturbances
Off-label and investigational uses
- Panic disorder
- Diabetic neuropathy
- Bulimia nervosa
- Obsessive-compulsive disorder (OCD)
- Alcohol withdrawal
- Schizophrenia and other psychosis
- Complex Regional Pain Syndrome